Abstract

Asymmetric dimethylarginine (ADMA) is an endogenous and competitive inhibitor of nitric oxide synthase. Plasma levels of this inhibitor are elevated in patients with atherosclerosis and in those with risk factors for atherosclerosis. In these patients, plasma ADMA levels are correlated with the severity of endothelial dysfunction and atherosclerosis. By inhibiting the production of nitric oxide, ADMA may impair blood flow, accelerate atherogenesis, and interfere with angiogenesis. ADMA may be a novel risk factor for vascular disease.

Original languageEnglish (US)
Pages (from-to)2032-2037
Number of pages6
JournalArteriosclerosis, Thrombosis, and Vascular Biology
Volume20
Issue number9
DOIs
StatePublished - 2000

Keywords

  • Arginine
  • Atherosclerosis
  • Nitric oxide
  • Vasodilation

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Fingerprint Dive into the research topics of 'Does ADMA cause endothelial dysfunction?'. Together they form a unique fingerprint.

Cite this